 |
|
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online 2022 Dec 5 DOI: https://doi.org/10.3350/cmh.2022.0318
|
|
Citations to this article as recorded by
 Genetic Variation in Angiotensin II Type 1 Receptor Is Linked to Lipid Levels and Hepatic Steatosis in Alcohol-Associated Liver Disease, but Not to Cirrhosis or Hepatocellular Carcinoma
Hans Dieter Nischalke, Franziska Schmalz, Janett Fischer, Christine Möller, Madlen Matz-Soja, Benjamin Krämer, Bettina Langhans, Jacob Nattermann, Thomas Berg, Christian P. Strassburg, Philipp Lutz
Gastroenterology Insights.2024; 15(1): 19. CrossRef Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making
Carlos J Pirola, Silvia Sookoian
Expert Review of Gastroenterology & Hepatology.2023; 17(4): 317. CrossRef The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
Marta Alonso-Peña, Maria Del Barrio, Ana Peleteiro-Vigil, Carolina Jimenez-Gonzalez, Alvaro Santos-Laso, Maria Teresa Arias-Loste, Paula Iruzubieta, Javier Crespo
International Journal of Molecular Sciences.2023; 24(13): 10718. CrossRef New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeongjun Song
Nutrients.2023; 15(18): 3970. CrossRef Waiting for the changes after the adoption of steatotic liver disease
Eileen L. Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef Genetic polymorphisms of CYP2B6 is a risk of metabolic associated fatty liver disease in Chinese population
Jingwei Zhang, Shijie Ma, Wei Zhou, Jing Feng, Yuwei Kang, Wei Yang, Heping Zhang, Fei Deng
Toxicology and Applied Pharmacology.2023; 481: 116770. CrossRef
|